In Berger et al.'s "Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men," the researchers performed a meta-analytical review to determine whether or not there was a gender-based difference in the risks and advantages experienced when aspirin is used to treat cardiovascular disease.
In this study, a number of studies from the MEDLINE and Cochrane Central Register of Controlled Trials databases were analyzed, in addition to bibliographies of the selected trials and major scientific reports. The inclusion criteria included those studies which were randomized and controlled trials of aspirin therapy for those people who did not ...